PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus

ConditionKeratoconus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstituto de Oftalmología Fundación Conde de Valenciana

About this trial

Keratoconus causes irregular astigmatism and reduced vision. Epi-off corneal crosslinking (CXL) stabilizes the cornea but often leaves higher-order aberrations uncorrected. This randomized, parallel-group trial compares corneal wavefront guided photorefractive keratectomy (corneal wavefront guided PRK, 50 µm therapeutic ablation) combined with accelerated epi-off CXL versus epi-off CXL with epithelial removal by phototherapeutic keratectomy (PTK) using a Schwind AMARIS excimer laser, in adults with keratoconus. The primary endpoint is change in best-corrected distance visual acuity (logMAR) at 12 months. Key secondary endpoints include Kmax, corneal higher-order aberrations, manifest refraction, Scheimpflug densitometry (haze) and Fantes grade, Corvis ST biomechanics, NEI VFQ-25, and endothelial cell density by non-contact specular microscopy at 1, 3, 6 and 12 months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-40 years

Diagnosis of keratoconus, ABCD Belin stage I-III at baseline

Minimum (thinnest) corneal pachymetry ≥ 450 µm pre-op

Written informed consent

Disqualifiers

Central corneal scars or opacities

Prior ocular surgery or trauma (exception: prior LASIK if it is the cause of post-surgical ectasia, per protocol text)

Autoimmune disease or uncontrolled diabetes mellitus

Pregnancy or lactation

Trial design

Design model

Parallel

Treatments tested in this trial

  • Schwind AMARIS excimer laser

    Device

    Used for corneal wavefront guided PRK therapeutic ablation (50 µm) or for PTK epithelial removal, according to arm assignment.

  • Corneal collagen crosslinking epi-off accelerated

    Procedure/Surgery

    Riboflavin-UVA crosslinking performed after epithelial removal (corneal wavefront guided PRK arm via PRK; comparator arm via PTK). Intensity: 30 mW/cm² (pulsed 1 s on / 1 s off; 50% duty cycle). Total energy (fluence): 5.4 J/cm². Total time (elapsed): 6 minutes \[equivalent to 3 minutes "on" time\].

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Corneal Wavefront Guided PRK + CXLExperimental treatment 2 interventions
Group B: PTK + CXLActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Change in best-corrected distance visual acuity (logMAR)

ETDRS-based CDVA in logMAR; change from baseline at 12 months; primary analysis by ANCOVA adjusted for baseline; one study eye per participant.

Time frame
Baseline to 12 months

Secondary outcomes

1

Change in Kmax (Diopters)

Pentacam Scheimpflug tomography; maximum keratometry (D); change from baseline at each time point.

Time frame
Baseline; 3; 6; 12 months
2

Change in corneal higher-order aberrations (µm RMS)

Wavefront/aberrometry total HOAs RMS (µm) over 6-mm pupil; change from baseline.

Time frame
Baseline; 3,6,12 months
3

Change in manifest refraction spherical equivalent (Diopters)

Manifest refraction SE (D); change from baseline.

Time frame
Baseline; 3;6;12 months
4

Corneal haze (Scheimpflug densitometry units)

CCT and corneal haze as measured by Pentacam Corneal Densitometry. Unit of measure: gray units.

Time frame
Baseline; 3;6;12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.